- Contributing to the United Nations Sustainable Growth Objectives, driving equitable entry to healthcare by know-how and innovation
- Enhancing governance transparency and effectiveness to create long-term worth for all stakeholders
- Empowering workers and fostering shared worth with communities
- Accelerating local weather actions and strengthening environmental stewardship
- Main Inexperienced CRDMO options to assist world purchasers’ sustainability journeys
HONG KONG, April 29, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a number one world Contract Analysis, Growth, and Manufacturing Group (CRDMO), right now introduced the discharge of its 2025 Sustainability Report. The report highlights the Firm’s continued dedication to putting sustainability on the core of its technique, empowering world purchasers, advancing progressive biologics to learn sufferers worldwide, and creating long-term worth for all stakeholders.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “At WuXi Biologics, we consider that long-term enterprise success is constructed on our duty to individuals, society, and the planet. As a acknowledged chief in sustainability, we’re dedicated to working collaboratively with all stakeholders to create optimistic social and environmental impacts, empowering our world purchasers by end-to-end Inexperienced CRDMO options, and driving accountable practices throughout all the worth chain.”
Enhancing Governance Transparency and Effectiveness
Guided by a complete sustainability technique, WuXi Biologics has put in place strong company governance buildings and well-defined administration processes. In alignment with the United Nations Sustainable Growth Objectives, the corporate has established science-based, measurable ESG goal matrix supported by an in depth roadmap to watch efficiency and allow steady enchancment.
WuXi Biologics is dedicated to open and clear engagement with stakeholders, and to constructing long-term, trusted partnerships. As an energetic participant of the Pharmaceutical Provide Chain Initiative (PSCI), the Firm adheres to PSCI rules throughout Ethics, Human Rights and Labor, Well being and Security, Atmosphere, and Administration Programs, and collaborates with world suppliers to advertise accountable practices. In 2025, WuXi Biologics achieved ISO 20400 Sustainable Procurement certification, additional strengthening provide chain resilience. The Firm has established a complete, end-to-end framework to guard mental property, commerce secrets and techniques, and information privateness by institutional, technical, and managerial safeguards, making certain efficient implementation throughout operations. In the meantime, the Firm continues to boost its enterprise resilience and danger administration capabilities by reaching ISO 22301 Enterprise Continuity Administration System certification, supporting steady world operations and public well being responses.
Empowering Individuals and Creating Shared Worth with Communities
WuXi Biologics extremely values the contributions of its world workforce and is pleased with its numerous, extremely skilled expertise base representing 51 nationalities. The Firm actively helps the profession growth of girls in Science, Expertise, Engineering and Arithmetic (STEM), with 54% of STEM positions held by feminine workers, considerably exceeding the trade common.
Group engagement stays a significant element of WuXi Biologics’ optimistic social impression. In 2025, workers contributed over 12,000 volunteer hours in native communities. The Firm additionally promoted nearer alignment between worker engagement and neighborhood wants by mobilizing volunteer efforts in neighborhood initiatives, contributing to larger social resilience.
Driving Equitable Entry to Healthcare by Expertise and Innovation
By shortening the timeline from molecules to sufferers, we allow progressive biologics to succeed in sufferers sooner, at larger scale, and with constant high quality — driving equitable entry to healthcare worldwide. Via the institution of a world, giant‑scale, finish‑to‑finish built-in CRDMO platform, the Firm continues to create lengthy‑time period worth in assist of world healthcare fairness and improved public well being outcomes.
Constructing on its core know-how capabilities, WuXi Biologics actively responds to world public well being wants by empowering companions to speed up the event and manufacturing of progressive therapies for sufferers all over the world. In 2025, the Firm has partnered with Instituto Butantan and Fundação Butantan in Brazil to assist the scaled industrial manufacturing for the dengue vaccine Butantan-DV, contributing to the strengthening of native public well being preparedness. The fill-and-finish facility serving this venture has obtained GMP certification from the Brazilian Well being Regulatory Company (ANVISA).
Uncommon illnesses stay a key focus of the Firm’s platform‑primarily based innovation. As of the top of 2025, there have been 23 uncommon illness initiatives on our platform. In Might 2025, accomplice CANbridge Prescribed drugs obtained approval from the Nationwide Medical Merchandise Administration (NMPA) for velaglucerase-beta for injection (Gaurunning®), marking a big milestone in advancing progressive uncommon illness therapies by collaboration.
As well as, the Firm is dedicated to supporting neighborhood well being by a spread of initiatives, together with emergency aid, major healthcare rebuilding, illness help, and neighborhood well being packages, repeatedly strengthening native healthcare programs and lengthening healthcare accessibility to the “final mile”.
From world public well being response to particular person care, WuXi Biologics leverages its built-in know-how platforms, resilient world community and unified world‑class high quality programs to repeatedly improve healthcare accessibility, safeguarding the well being and well-being of sufferers worldwide.
Accelerating Actions for Tackling Local weather Change and Selling Environmental Stewardship
The Firm continues to boost environmental stewardship throughout local weather change mitigation, useful resource effectivity, round economic system practices, ecosystem safety and inexperienced innovation.
In 2025, WuXi Biologics launched a brand new and bold greenhouse gasoline emission goal matrix that was validated by the Science Based mostly Targets initiative (SBTi). The Firm additionally achieved its water administration goal of lowering water consumption depth by 30% from the bottom 12 months 2019 and rolled out its Water Excellence Stewardship program throughout 10 websites. To assist broader trade sustainability, WuXi Biologics revealed the Inexperienced CRDMO White Paper, detailing its inexperienced analysis, growth and manufacturing practices, and highlighting energy-saving and carbon-reduction outcomes enabled by inexperienced operations.
To drive steady enchancment for operational excellence, WuXi Biologics Enterprise System (WBS) applies lean administration rules and integrates with sustainability technique. In 2025, over 95% of WBS Kaizen initiatives generated measurable ESG advantages, together with reductions in carbon emission, water consumption and waste era.
World Affect, Shared Future
WuXi Biologics’ constant efforts to advertise sustainable growth have obtained notable recognition from main world ESG ranking businesses. These recognitions embody an MSCI AAA ESG ranking; an EcoVadis Platinum Medal; inclusion within the Dow Jones Greatest-in-Class Indices (previously Dow Jones Sustainability Indices); CDP “A Checklist” standing for Local weather Change, Water Safety, and Provider Engagement Evaluation; the best negligible-risk ESG ranking by Sustainalytics; inclusion within the FTSE4Good Index Sequence; a “Prime” designation from ISS ESG Company Score; and inclusion within the Dangle Seng Company Sustainability Benchmark Index.
Dr. Chris Chen commented, “Looking forward to 2026 and past, we are going to construct on our robust momentum to speed up development, pushed by strong analysis, growth and manufacturing capabilities. With sustainability on the core of how we innovate, function, and develop, WuXi Biologics will proceed to empower world purchasers to carry life-changing therapies to sufferers worldwide, whereas delivering long-term worth and shared success for all stakeholders in pursuit of a more healthy future.”
Obtain 2025 Sustainability Report
https://www.wuxibiologics.com/wp-content/uploads/E_898490_WUXI-BIO_ESG2025_0429_1713_ESS.pdf
About WuXi Biologics
WuXi Biologics (inventory code: 2269.HK) is a number one world Contract Analysis, Growth and Manufacturing Group (CRDMO) providing end-to-end options that allow companions to find, develop and manufacture biologics – from idea to commercialization – for the good thing about sufferers worldwide.
With over 13,000 workers in China, the US, Eire, Germany, and Singapore — together with specialists and scientists in biologics R&D and manufacturing, know-how innovation, and operational excellence — WuXi Biologics leverages its applied sciences and experience to ship environment friendly, cost-effective, and scalable biologics options tailor-made to satisfy purchasers’ wants. By embedding digital functionality and infrastructure throughout the total biopharmaceutical worth chain, the corporate turns information, computation, and prediction into clear shopper expertise, sooner growth, clever operations, and extra environment friendly manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 built-in shopper initiatives, together with 74 in Section III and 25 in industrial manufacturing, with advanced modalities representing greater than half of all the venture portfolio.
WuXi Biologics regards sustainability because the cornerstone of long-term enterprise development. The corporate repeatedly drives know-how improvements to supply superior end-to-end Inexperienced CRDMO options for its world companions whereas demonstrating exemplary Environmental, Social and Governance (ESG) practices. Dedicated to creating shared worth, it collaborates with all stakeholders to foster optimistic social and environmental impacts and promote accountable practices that empower all the worth chain.
For extra details about WuXi Biologics, please go to: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
View authentic content material:https://www.prnewswire.com/news-releases/wuxi-biologics-releases-2025-sustainability-report-advancing-sustainable-growth-and-improving-healthcare-access-302757229.html
SOURCE WuXi Biologics
